ClinicalTrials.gg
CompletedNCT00165815Updated May 10, 2013

The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia

A Phase 3 interventional study of ARICEPT in Dementia With Parkinson's Disease, sponsored by Eisai Limited. Completed at 4 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2013-05-10.

Sponsored by Eisai Limited · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 26 studies testing donepezil in Dementia — none open to participants now, none under way, none of them phase 3. Donepezil · Dementia.

Started
2002
with 1 other
Phase 3
8 of 26
none open now
Registered
7th of 26
by date
Lead sponsor
2 of 26
Eisai Limited

Among the 26 studies testing donepezil in Dementia, this one is one of 2 that started in 2002, is one of 8 in phase 3, and was the 7th registered.

Dementia

2,376 studies on the registry are indexed under Dementia; 573 are open to participants now.

Browse Dementia studies →

Open to participants now

None of the 26 studies testing donepezil in Dementia is open now. The open studies under Dementia, anywhere →

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 382 Dementia studies recruiting now, 243 (64%) set no upper age limit and 25 (7%) stop at 75 or younger; 16 take children under 18; 163 take healthy volunteers.

This study: 40 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing donepezil in Dementia as a file.
02

Study summary

A randomised, double-blind, 3-arm parallel group study comparing Aricept® with placebo.

03

Conditions studied

  • Dementia With Parkinson's Disease
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All

Eligibility criteria

Patients with an established diagnosis of PD and dementia, who fulfill all of the inclusion criteria and none of the exclusion criteria listed below, will be eligible for enrolment into this study.

Best efforts must be made on clinical grounds to exclude patients with DLB and AD. The key inclusion criteria in this respect is the onset of dementia documented to have occurred at least 1 year after the diagnosis of PD.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double

Interventions

06

What researchers measure

Primary outcomes

  1. PD patients with dementia will be screened up to 4 weeks prior to initiating dose administration. Baseline measurement on efficacy measures will be conducted at baseline, after which the first dose of study medication will be administered.

07

Study locations

4 sites
  • Allgemeines Krankenhaus Barmbeck
    Hamburg, Hambug, Germany
  • Parkinson Klinik Wolfach
    Wolfach, Germany
  • Belfast City Hospital
    Belfast, Ireland
  • Unit 20 Black Poo Technology Centerl
    Blackpool, Ireland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2002 and a completion of Jul 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 14, 2005
Start
Aug 2002
Completion
Jul 2005
Last update
May 10, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on May 10, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00165815
Lead sponsor
Eisai Limited
First posted
Sep 14, 2005
Start date
Aug 2002
Completion
Jul 2005
Last update
May 10, 2013

Study contacts

Jina Schwartz
study director · Eisai Limited
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion